Checkpoint Therapeutics, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Segment Information (Tables)

Segment Information (Tables)

12 Months Ended

Dec. 31, 2024

Schedule of significant segment expenses

For the years ended December 31, 2024 and 2023, the significant expense categories regularly provided to the CODM consisted of the following (in thousands):


	For the year ended December 31,
	2024		2023
Revenue - related party	$	41	$	103

Operating expenses:
Employee Expenses		8,624		7,285
Stock-based Compensation		15,252		2,897
Fortress Founder's Agreement and MSA Expenses		9,133		4,871
Manufacturing and Development Expenses		10,755		19,013
Clinical Expenses		3,901		6,981
Regulatory Expenses		334		3,615
License Fees		152		2,300
Legal & Accounting Expense		4,123		1,814
R&D Other Expense ⁽¹⁾		1,629		1,439
G&A Other Expense ⁽²⁾		2,312		2,036
Total Operating Expenses		56,215		52,251

Other Segment Items ⁽³⁾		(66)		301
Net Loss	$	(56,240)	$	(51,847)

(1) R&D Other Expense includes travel, consulting, and outside service expenses.

(2) G&A Other Expense includes travel, consulting, marketing, business development, investor relations and outside services expenses.

(3) Other Segment Items include interest income, foreign currency exchange loss, and gain (loss) on common stock warrant liabilities.